Loading company…
Velabs Therapeutics GmbH develops biotherapeutics, including monoclonal antibodies, mainly for oncology and autoimmune disorders.
Founded in 2017 in Heidelberg, Germany, Velabs Therapeutics sells its therapeutic products to hospitals and specialty clinics, and also works through strategic partnerships with healthcare organizations. Founder Christoph Merten has a background in biotechnology. The company raised EUR 3.00 mn in Series B funding on June 11, 2019, led by Vertex One Asset Management alongside EMBLEM Technology Transfer.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in